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Abstract In the present study we show that the H (0) blood
group determinant FucK1-2GalL1-4GlcNAcL1-R is present on
N-linked glycans of soluble human L-selectin recombinantly
expressed in baby hamster kidney (BHK) cells. The glycans were
isolated using complementary HPLC techniques and character-
ized by a combination of exoglycosidase digestion and mass
spectrometry. The linkage of the fucose residues was determined
by incubation of the glycans with specific fucosidases. The H
blood determinant FucK1-2GalL1-4GlcNAcL1 was detected for
bi-, 2,4 branched tri- and tetraantennary structures. To our
knowledge, the proposed oligosaccharide structures represent a
new glycosylation motif for recombinant glycoproteins expressed
on BHK cells.
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1. Introduction
L-selectin is a member of the selectin family of adhesion
proteins. Selectins mediate the process of rolling, the initial
step of extravasation of leukocytes from the blood stream,
either into in£amed tissues [1] or into peripheral lymph nodes
[2]. Rolling of leukocytes along the endothelium of blood
vessels is induced by binding of selectins to surface carbohy-
drate ligands expressed on endothelial cells or on leukocytes
[3]. While the recruitment of leukocytes to sites of in£amma-
tion is a desired action of the immune system, excessive leu-
kocyte tra⁄cking contributes to severe tissue destruction [4].
Many strategies have been published for blocking the inter-
action of selectins with their carbohydrate ligands. We are
interested in the competitive prevention of cell-cell adhesion
by circulating soluble forms of L-selectin (sL-selectin). During
the process of rolling L-selectin is cleaved by an unknown
protease and released from the cell surface [5]. The shed
form of sL-selectin remains bioactive, and can inhibit L-selec-
tin mediated adhesion in a concentration dependent manner
[6]. For the structural and biochemical characterization of sL-
selectin, the cDNA was cloned and overexpressed in baby
hamster kidney (BHK) cells. Recombinant sL-selectin (rsL-
selectin) consists of distinct domains, including an amino-ter-
minal C-type lectin domain, one EGF-like domain and two
short consensus repeat domains. The polypeptide backbone
contains seven potential N-glycosylation sites, but the struc-
tures of the carbohydrate moiety of natural and recombinant
sL-selectin are still unknown. In the present report we de-
scribe the structural characterization of N-linked glycans car-
rying the H (0) blood group determinant which was unexpect-
edly found for rsL-selectin expressed in BHK cells.
2. Materials and methods
2.1. Materials
rsL-selectin from BHK cells was provided by the group of Prof.
Tauber (Freie Universita«t Berlin, Germany). Trypsin was obtained
from Serva (Heidelberg, Germany) and tri£uoroacetic acid was ob-
tained from Sigma (Deisenhofen, Germany). PNGase F, neuramini-
dase, L-N-acetylhexosaminidase and L-galactosidase were purchased
from Boehringer Mannheim (Mannheim, Germany). Signal Labeling
Kit was obtained from Oxford GlycoSciences (Abingdon, UK). Fu-
cosidase II and III were purchased from Dextra (Reading, UK).
2.2. Tryptic digestion of rsL-selectin
Tryptic digestion of rsL-selectin (3 nmol) was performed overnight
at 37‡C in 45 Wl of a bu¡er containing 50 mM N-methyl-2,2-imino-
diethanol, pH 8.0, by addition of two portions of trypsin (1/100 w/w)
at 0 h and 8 h. The incubation was stopped by heat inactivation of
trypsin (100‡C for 5 min).
2.3. Release of N-glycans by PNGase F digestion
Tryptic glycopeptides obtained from 3 nmol rsL-selectin were di-
gested with 5 mU PNGase F from Flavobacterium meningosepticum in
50 Wl of a bu¡er containing 50 mM N-methyl-iminodiethanol, pH 8.0,
for 18 h at 37‡C.
2.4. Fluorescent labeling of the glycans
Released N-glycans were £uorescently labeled by reductive amina-
tion with 2-aminobenzamide (2-AB) using a Signal Labeling Kit ac-
cording the protocol of the manufacturer. Excess 2-AB was removed
by paper chromatography as described earlier [7].
2.5. Desialylation
Fluorescently labeled N-glycans (about 20 nmol) were treated with
0.1 U neuraminidase from Vibrio cholerae in 80 Wl of 50 mM sodium
acetate bu¡er, pH 5.5, overnight at 37‡C.
2.6. Separation of desialylated N-glycans
Desialylated 2-AB-labeled N-glycans were separated by amino-
phase HPLC using an APS 2-Hypersil column (4U250 mm, 3 Wm,
Bischo¡ (Leonberg, Germany)) at room temperature at a £ow rate of
1.5 ml/min. Glycans were eluted by a two-step gradient, consisting of
solvent A (acetonitrile) and solvent B (15 mM sodium phosphate, pH
5.2) starting from 0% solvent B to 20% B in 10 min then to 50% B
within 100 min.
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Obtained glycan fractions were rechromatographed by RP-18
HPLC using an ODS-Hypersil column (4U250 mm, Knauer (Berlin,
Germany)) at room temperature at a £ow rate of 1 ml/min. After
injection of the sample, the column was eluted with 7 ml H2O, fol-
lowed by a linear gradient up to 25% acetonitrile within 75 min. The
applied two-dimensional HPLC-based separation was described in de-
tail recently [7].
2.7. Oligosaccharide sequence analysis
The glycan fractions were enzymatically sequenced by incubation
with a mixture of L-N-acetylhexosaminidase and L-galactosidase, both
from Streptococcus pneunomiae [8]. Exoglycosidase digestion was per-
formed at an enzyme concentration of 50 mU/ml for L-galactosidase
and 50 mU/ml for L-N-acetylhexosaminidase in 25 mM NH4OAc, pH
5.5, overnight (37‡C). Digestion products were analyzed with matrix
assisted laser desorption/ionization time of £ight mass spectrometry
(MALDI-TOF-MS). Digestion of the glycan fractions with fucosidase
II or fucosidase III was performed in the same bu¡er at an enzyme
concentration of 10 mU/ml in a ¢nal volume of 20 Wl according to the
protocol of the manufacturer. Digestion products were analyzed with
MALDI-TOF-MS.
2.8. Mass spectrometry
MALDI-TOF-MS was carried out as described previously [9]. 6-
Aza-2-thiothymine was used as a matrix as reported by Papac et al.
[10].
3. Results
3.1. Isolation and mass determination of the bifucosylated
N-glycans
The asparagine-linked sugar chains of rsL-selectin were en-
zymatically released from tryptic peptides by digestion with
PNGase F and £uorescently labeled with 2-AB. Puri¢ed oligo-
saccharides were desialylated by incubation with neurami-
nidase. Desialylation was performed to reduce the structural
heterogeneity of the glycans and to facilitate the analysis of
side compounds.
Separation of the asialo oligosaccharides using amino-phase
HPLC yielded an elution pattern with three main signals and
several minor signals representing the heterogeneity of N-gly-
cans (Fig. 1). All peaks were subjected to mass determination
by MALDI-TOF-MS. Pseudomolecular ions of most fractions
were consistent with masses of common complex-type N-gly-
cans. The main signals F1, F3 and F5 consist of monofucosyl-
ated bi-, tri- and tetraantennary structures, respectively. Mass
determination of minor fractions F2, F4 and F6 resulted in
ions consistent with bi-, tri- and tetraantennary glycans carry-
ing two deoxyhexose residues (Table 1). Since coeluting sugars
were still present in these fractions, reversed phase chroma-
tography was used to obtain homogeneous glycan fractions
for further structure determination. Rechromatography of F2,
F4 and F6 yielded several subfractions. Mass spectrometry
Fig. 1. Separation of desialylated 2-AB labeled N-glycans from rsL-
selectin. The N-linked glycans were enzymatically released and £uo-
rescently labeled with 2-AB. After desialylation by incubation with
neuraminidase, the neutral N-glycans were separated using amino-
phase HPLC. The main signals F1, F3 and F5 represent bi-, tri-
and tetraantennary structures with one fucose residue, while F2, F4
and F6 were found to contain two fucoses. These fractions were
subjected to further structural characterization by exoglycosidase di-
gestion and mass determination.
Table 1
Mass determination and enzymatic sequencing of bifucosylated N-glycans
OS fractiona Ions m/z (Mcalc+Na) Composition Digestion with
before digestion Fuc’ase II Gal’ase/GlcNAc’ase after fuc’ase II Gal’ase/GlcNAc’ase




F2.2 2077 2076.9 32 GlcNAc 31 GlcNAc




F4.2a 2443 2442.2 32 GlcNAc 31 GlcNAc
F4.2b 2442 2442.2 d-
Hex2Hex6HexNAc5
31 Fuc 33 Gal 32 Gal
32 GlcNAc 32 GlcNAc
F6.1 2807 2807.6 d-
Hex2Hex7HexNAc6
31 Fuc 34 Gal 33 Gal
F6.2 2808 2807.6 31 GlcNAc 31 GlcNAc
Masses of desialylated oligosaccharides were determined before and after digestion with exoglycosidases by MALDI-TOF-MS. Applied enzymes
were fucosidase II (Fuc’ase II) and a mixture of L1-4 galactosidase/N-acetylglucosaminidase from S. pneumoniae (Gal’ase/GlcNAc’ase). The
number of released residues of fucose (Fuc), galactose (Gal) and N-acetylglucosamine (GlcNAc) is given. Monitored ions consist of the Na ad-
ducts (M+Na) of the glycans (values are rounded). Mcalc refers to the calculated average molecular mass (in Da) summed from the likely car-
bohydrate composition plus the 2-AB label.
aOS fraction: oligosaccharide fraction numbers refer to the glycan fractions from the amino-phase HPLC and the subsequent reversed phase
HPLC.
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revealed the presence of bifucosylated sugars in designated
fractions F2.1, F2.2, F4.1, F4.2, F6.1 and F6.2.
3.2. Structural characterization of the bifucosylated N-glycans
The bifucosylated sugars were digested with exoglycosidases
to determine the linkage of the fucose residue to the antennae,
type of antennae and branching of the N-glycans, as well as
the linkage of the fucosylated antennae to the glycan core.
The reaction products were detected by MALDI-TOF-MS
(Fig. 2).
3.2.1. Linkage of the fucose residue to the antennae. The
linkage of the fucose residues was characterized using fucosi-
dase III, which speci¢cally cleaves fucose K1-3/4 linked to N-
acetylglucosamine, and fucosidase II, which releases fucose
K1-2 linked to galactose. Treatment of the bifucosylated gly-
cans from rsL-selectin with fucosidase III did not result in a
loss of fucose residues. Surprisingly, after incubation with
fucosidase II, one fucose residue was released from each frac-
tion. Based on the speci¢city of the applied enzymes, we con-
clude that the H (0) blood group determinant FucK1-2Gal is
present in the antennae of these glycans (Table 2).
3.2.2. Type of antennae and branching of the N-
glycan. The glycans obtained after digestion with fucosidase
II were further characterized by incubation with a mixture of
galactosidase and N-acetylglucosaminidase, both from S.
pneumoniae. The applied galactosidase cleaves GalL1-
4GlcNAc/GalNAc but does not act on GalL1-3GlcNAc/Gal-
NAc at low enzyme concentrations. Under the experimental
conditions used, the L-N-acetylhexosaminidase cleaves L1-2
linked GlcNAc unless the mannose to which it is linked has
an additional substituent at C-6.
Mass spectrometry revealed that all galactose residues were
released from the oligosaccharides. Thus all antennae consist
of the structural element GalL1-4GlcNAc, known as a type II
chain. Glycans of fractions F2.1 and F2.2 were degraded to
the fucosylated pentasaccharide core. For fractions F4.1 and
F4.2 all isomers were converted into the fucosylated core
structure plus one HexNAc residue, suggesting the presence
of a 2,4 branched triantennary oligosaccharide for the undi-
gested glycans. Exoglycosidase treatment of fractions F6.1
and 6.2 resulted in glycan fragments consistent with the fuco-
sylated core plus three HexNAc residues, as expected for a
tetraantennary structure.
3.2.3. Linkage of the fucosylated antennae to the glycan
core. To characterize the linkage of the fucosylated antennae
to the glycan core we incubated all glycan fractions with a
mixture of L1-4 galactosidase and N-acetylglucosaminidase,
both from S. pneumoniae, without prior incubation with fu-
cosidase. In every case, the fucosylated galactose was not
released by digestion with galactosidase. Mass analysis of
the obtained glycan fragments yielded ions consistent with
the release of two galactose and one N-acetylglucosamine res-
idues for fraction F4.1. Incubation of fraction F4.2 resulted in
two glycans with masses corresponding to the removal of two
Fig. 2. MALDI-TOF-MS spectra of a tetraantennary glycan containing two fucose residues (fraction 6.1). Mass determination was performed
of the undigested 2-AB labeled glycan (A) and after treatment with the following exoglycosidases: fucosidase II (B), a mixture of L1-4 galacto-
sidase and N-acetylglucosaminidase from S. pneumoniae before (C) and after digestion with fucosidase II (D). Glycan key: 7= galactose,
F= N-acetylglucosamine, b= mannose, O= fucose.
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galactose and one (F4.2a) or two N-acetylglucosamine resi-
dues (F4.2b). This result indicated the presence of three iso-
meric forms of 2,4 branched triantennary structures carrying
two fucose residues in F4.1 and F4.2. However, the two po-
tential isomers modi¢ed on the di¡erent 2P-arms of the 224
triantennary glycan cannot be distinguished by this method.
Mass determination of digested fractions F6.1 and F6.2 was
consistent with the release of three galactose and one N-ace-
tylglucosamine residue. This indicated that the antennae
linked to the 2 position of the 2,4 branched mannose in the
core does not carry the fucose residue. The results of the
enzymatic sequencing of the glycans are compiled in Table
1. From the mass spectrometric data of enzymatically se-
quenced N-glycans we propose the structures for these oligo-
saccharides shown in Table 2.
4. Discussion
The present study shows that the H (0) blood group deter-
minant FucK1-2GalL1-4GlcNAcL1-R is present in bi-, tri- and
tetraantennary N-glycans of rsL-selectin expressed in BHK
cells.
The H (0) blood group determinant FucK1-2GalL1-3/
4GlcNAcL1-R is the precursor of the blood group antigens
A and B of the ABO system, as well as the Lewisb and Lewisy
structures. The H structure is synthesized from GalL1-3/
4GlcNAcL1-R by the action of an K1-2-fucosyltransferase
(K1-2FT). At least two K1-2FTs are present in human tissues.
The K1-2FT determined at the secretor locus regulates the
expression of the H determinant in epithelial cells and body
£uids [11]. The K1-2FT encoded at the H gene locus catalyzes
the synthesis of the H determinant which is mainly exhibited
on the membranes of erythrocytes [12].
The structures carrying the H determinant of rsL-selectin
are common bi-, tri- and tetraantennary N-glycans that lack
polylactosamine sequences but are K1-6 fucosylated in the
core pentasaccharide. These glycan structures are abundant
on many human glycoproteins in the blood plasma and on
the cell surface but might be low a⁄nity substrates of K1-2FT
[13,14]. Only a few human plasma derived glycoproteins have
been identi¢ed that contain minor levels of ABO blood group
antigens. Some of the N-glycans on human K2-macroglobulin
are modi¢ed by the H-structure [15]. Analysis of the associ-
ated proteins of factor VIII [16] and von Willebrand Factor
Table 2
Proposed structures for the N-linked glycans released from rsL-selectin carrying the H (0) blood group determinant
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has revealed the presence of ABO-determinants on bi- and
triantennary sugar chains [17]. It should be noted that factor
VIII recombinantly expressed in BHK-cells does not contain
ABO-structures while factor VIII derived from human plasma
does. On human erythrocytes these determinants are predom-
inantly linked to N-acetyllactosamine repeats, as demon-
strated for band 3, the major ABO(H) containing glycopro-
tein on human erythrocytes [18]. N-Glycans carrying the ABO
determinants have also been identi¢ed for human pancreatic
elastase 1 [19], the carcinoembryonic antigen and non-speci¢c
cross-reacting antigen-2 [20,21]. In addition, blood group de-
terminants have been determined in the O-linked sugar chains
of some secreted human glycoproteins [22^25].
BHK and CHO cells are frequently used for the expression
of recombinant glycoproteins, in particular of recombinant
therapeutic agents. The glycosylation motifs synthesized by
BHK and CHO cells have been extensively investigated (for
review see [26]) and some glycoproteins were found to carry
unique features. In general fucosylation is limited to the inner-
most residue of N-acetylglucosamine in the core of N-glycans,
but outer chain fucosylation has been reported for recombi-
nant factor VIII from BHK cells [16]. The antigenic GalK1-
3Gal epitope has been found in human soluble CD4 variant
form CHO cells [27] and in factor VIII derived from BHK
cells [16]. Erythropoietin is the only secreted protein of BHK
cells that possesses mannose 6-phosphate containing N-gly-
cans [28]. To our knowledge the occurrence of the H deter-
minant in a recombinant protein from BHK cells has not
hitherto been reported. The presence of the H determinant
might result from the activation of a silent endogenous K1-
2FT, or more unlikely the activity of an K1-2FT that recog-
nizes a peptide sequence. Unexpected activation of endoge-
nous glycosyltransferases has important implications for the
production of recombinant therapeutic agents, since particular
oligosaccharides of glycoproteins are known to be immuno-
genic [29].
At least two immunogenic carbohydrate epitopes, GalK1-
3Gal and N-glycolylneuraminic acid, can be synthesized by
CHO and BHK cells. Factor VIII from BHK cells was found
to carry about 3% of the GalK1-3Gal epitope [16]. In human
sera approximately 1% of the circulating IgG is directed
against this epitope [30]. However, clinical studies showed
that the half-life of factor VIII was not reduced by the expo-
sure of the GalK1-3Gal epitope [31]. Glycoconjugates contain-
ing N-glycolylneuraminic acid are immunogenic in human and
can induce antibodies, called Hanganutziu-Deicher antibodies.
Recombinantly expressed tissue type plasminogen activator,
chimeric plasminogen activator, follitropin and erythropoietin
(EPO) from CHO cells contain about 3% N-glycolylneura-
minic acid in total sialic acid content [32]. In patients who
received EPO from CHO cells no elevated levels of Hanga-
nutziu-Deicher antibodies were detected and it was concluded
that N-glycolylneuraminic acid present in recombinant EPO is
minimally antigenic in humans [33]. The H blood group de-
terminant is present in glycolipids and N-acetyllactosamine
repeats of N-glycans on the erythrocytes of all humans, except
humans of the rare Bombay and para-Bombay phenotypes,
and is not considered to be immunogenic. Whether the H (0)
blood group determinant in bi-, tri- and tetraantennary N-
glycans of rsL-selectin contributes to immunogenicity remains
open.
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